Status:
ACTIVE_NOT_RECRUITING
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
Lead Sponsor:
The National Center of Oncology, Azerbaijan
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE2
Brief Summary
The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer
Detailed Description
Using combination of gemcitabine plus cisplatine as first line treatment patients with locally advanced breast cancer with high TUBB3 expression
Eligibility Criteria
Inclusion
- IIIC stage breast cancer patients
Exclusion
- Other stages breast cancer patients
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06531447
Start Date
May 1 2014
End Date
May 1 2027
Last Update
August 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Elchin Mansurov
Baku, Azerbaijan, AZ1011